These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association. Lee S Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644 [TBL] [Abstract][Full Text] [Related]
4. SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review. Rastogi A; Bhansali A Diabetes Ther; 2017 Dec; 8(6):1245-1251. PubMed ID: 29076040 [TBL] [Abstract][Full Text] [Related]
5. The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data. Gallwitz B Eur Endocrinol; 2018 Apr; 14(1):17-23. PubMed ID: 29922347 [TBL] [Abstract][Full Text] [Related]
6. SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus. d'Emden M; Amerena J; Deed G; Pollock C; Cooper ME Diabetes Res Clin Pract; 2018 Feb; 136():23-31. PubMed ID: 29196150 [TBL] [Abstract][Full Text] [Related]
7. The kidney and cardiovascular outcome trials. Bloomgarden Z J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006 [TBL] [Abstract][Full Text] [Related]
8. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878 [TBL] [Abstract][Full Text] [Related]
9. Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio. Kaneko M; Narukawa M Clin Drug Investig; 2019 Feb; 39(2):179-186. PubMed ID: 30506378 [TBL] [Abstract][Full Text] [Related]
10. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Carbone S; Dixon DL Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195 [TBL] [Abstract][Full Text] [Related]
11. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials. Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426 [TBL] [Abstract][Full Text] [Related]
12. Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond. Oral EA Drugs Context; 2016; 5():212299. PubMed ID: 27648101 [TBL] [Abstract][Full Text] [Related]
13. [Cardiovascular and renal protection with SGLT2 inhibitors: from EMPA-REG OUTCOME to VERTIS CV]. Scheen AJ Rev Med Suisse; 2020 Aug; 16(703):1483-1488. PubMed ID: 32852168 [TBL] [Abstract][Full Text] [Related]
14. Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect? Ampudia-Blasco FJ; Romera I; Ariño B; Gomis R Int J Gen Med; 2017; 10():23-26. PubMed ID: 28144158 [TBL] [Abstract][Full Text] [Related]
15. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes? Saisho Y Diseases; 2020 May; 8(2):. PubMed ID: 32403420 [TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Pancholia AK Indian Heart J; 2018; 70(6):915-921. PubMed ID: 30580866 [TBL] [Abstract][Full Text] [Related]
17. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. Mima A J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432 [TBL] [Abstract][Full Text] [Related]